Abstract
Recently, two liposomal anthracycline formulations have been approved by the U.S. Food and Drug Administration for clinical use (Doxil, DaunoXome).1–3 Another formulation (D-99)4 is in advanced clinical trials. As these products become available to an enlarged circle of clinicians and nurses, the need to recognize their toxicity profile becomes more urgent. When a drug is presented in a liposome formulation, the medical teams are faced with a new entity which does not fit the usual definition of a new drug. This new entity is more complex than a simple drug since it consists of a carrier, the liposome, and a drug, which may be an approved and well-known drug (e.g., doxorubicin or daunorubicin) or a newly-designed drug (e.g., annamycin5). Some clinicians tend to look at liposomal doxorubicin or liposomal daunorubicin as another drug analog among the many (epirubicin, mitoxantrone, idarubicin) that have become available in recent years. Moreover, many clinicians will refer to liposomal anthracyclines as a homogeneous group of formulations with relatively similar pharmacological and biological effects. These are dangerous oversimplifications. A learning process is required to grasp the novelty and complexity of liposome-based drug delivery systems.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1995; 13: 914–920.
Uziely B, Jeffers S, Isacson R et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777–1785.
Gill PS, Espina BM, Muggia F et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995; 13:996-1003.
Cowens JW, Creaven PJ, Greco WR et al. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993; 53: 2796–2802.
Zou Y, Priebe W, Stephens LC et al. Preclinical toxicity of liposome-incorporated Annamycin: Selective bone marrow toxicity with lack of cardiotoxicity. Clin Cancer Res 1995; 11369-1374.
Lasic DD. Liposomes: From Physics to Applications. Amsterdam: Elsevier, 1993.
Gregoriadis G. Liposomes as Drug Carriers: Recent Trends and Progress. Chichester: John Wiley & Sons, 1988.
Gabizon A. Liposomes as a drug delivery system in cancer chemotherapy. In: Roerdink FH, Kroon AM, eds. Drug Carrier Systems. Biochemical and Biophysical Basis and Medical Prospects. Horizons in Biochemistry and Biophysics. Chichester: Wiley, 1989; 9: 185–211.
Barenholz Y, Cohen R. Rational design of amphiphile-based drug carriers and sterically stabilized carriers. J Liposome Res 1995; 5: 905–932.
Goren D, Gabizon A, Barenholz Y. The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior. Biochim Biophys Acta 1990; 1029:285-294.
Gabizon A. Liposome circulation time and tumor targeting: Implications for cancer chemotherapy. Adv Drug Deliv Rev 1995; 16:285-294.
Young RC, Ozols, RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981; 305: 139–153.
Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Int Med 1979; 91: 710–717.
Gabizon A. Liposomal anthracyclines. Hematol. Oncol Clin North Am 1994; 8: 431–450.
Haran G, Cohen R, Bar LK et al: Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochem Biophys Acta 1990; 1025: 143–151.
Lasic DD, Frederik PM, Stuart MC et al: Gelation of liposome interior-A novel method for drug encapsulation. FEBS Lett 1992; 312: 255–258.
Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochem Biophys Acta 1992; 1113: 171–199.
Sculier JP, Coune A, Brassinne C et al. Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent: A pilot study with pharmacokinetic data. J Clin Oncol 1986; 4: 789–797.
Szebeni J, Wassef NM, Spielberg H et al. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem Biophys Res Corn 1994; 205255-z63.
Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin. J Nail Cancer Inst 1995; 87:1556-1557.
Gabizon A, Pappo 0, Goren D et al. Preclinical studies with doxorubicin encapsulated in polyethyleneglycol-coated liposomes. J Liposome Res 1993; 3: 517–528.
Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Int Med 1984; 101: 798–800.
DeSpain JD. Dermatologic toxicity. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore: Williams & Wilkins, 1992: 531–547.
Gabizon A, Catane R, Uziely B et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987–992.
Billingham ME, Mason JW, Bristow MR et al. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865–869.
Daemen T, Hofstede G, Ten Kate MT et al. Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer 1995; 61: 716–721.
Storm G, Ten Kate MT, Working PK et al. Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononudear phagocyte system. Clin Cancer Res (submitted).
Muggia F, Hainsworth J, Jeffers S et al. Phase II study of liposomal doxorubicin (Doxil) in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15:987-993.
Guaglianone P, Chan K, DelaFlor-Weiss E et al. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest. New Drugs 1994; 12: 103–110.
Vermorken JB, Kobierska A, Chevallier B et al. Phase II study of high-dose epirubicin (HDE) in ovarian cancer patients previously treated with cisplatin. Proc Amer Soc Clin Oncol 1995; 14: 276 (Abstr 772).
Ranson M, O’Bryne K, Carmichael J et al. Phase II dose-finding trial of Dox-SL (Stealth liposomal doxorubicin HC1) in the treatment of advanced breast cancer. Proc Am Soc Clin Oncol 1996; 15: 124 (Abstr 161).
Gabizon A, Uziely B, Lotem M et al. Doxil in patients with pretreated metastatic breast cancer (MBC): a dose-schedule finding study with pharmacokinetics. Proc Am Soc Clin Oncol 1997; 16: 147a (Abstr 516).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Gabizon, A.A., Muggia, F.M. (1998). Initial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid Tumors. In: Woodle, M.C., Storm, G. (eds) Long Circulating Liposomes: Old Drugs, New Therapeutics. Biotechnology Intelligence Unit. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22115-0_11
Download citation
DOI: https://doi.org/10.1007/978-3-662-22115-0_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-22117-4
Online ISBN: 978-3-662-22115-0
eBook Packages: Springer Book Archive